As the COVID-19 continues to affect every aspect of life, the MedTech industry perseveres in its attempt to adapt and continue moving forward. SAWC and the Wound Healing Society held the SAWC Spring 2020 as a virtual experience on July 24-26. In their words "At a time when so much else is canceled, the work to treat, manage, and prevent chronic wounds and improve patient care cannot stop. Hope must go on."

The following is a small sampling of the updates compiled, reviewed and posted in real time last week by our SmartTRAK analysts, including many from SAWC 2020. We constantly monitor the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, financial data and competitor developments in the global Life Sciences industry.

SmartTRAK, the leading source of competitive intelligence used by the top global orthopedic & wound care companies, had four articles featured in the International Cartilage Regeneration & Joint Preservation Society Summer 2020 Issue. These articles were originally published on the SmartTRAK platform.

The ICRS is the main forum for international collaboration in cartilaginous tissue research and joint preservation whose stated mission is "Advancing Science & Education of the Prevention & Treatment of Cartilage Disease Worldwide."

Kim French, SmartTRAK's Senior Analyst, OrthoBio, had three of her articles included in the Summer 2020 issue:

As the COVID-19 pandemic progresses and continues to affect everyday life around the world, the path that lies ahead for the MedTech industry and the search for effective therapeutics and vaccines remains hard to predict.

The following is a small sampling of the updates compiled, reviewed and posted in real time last week by our SmartTRAK analysts. We constantly monitor  the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, financial data and competitor developments in the global Life Sciences industry.

The orthobiologics market continues to ramp up studies and new product development as surgeries impacted by COVID-19 are rescheduled. The following is a small sampling of the OrthoBio updates compiled, reviewed and posted in real time last week by our SmartTRAK analysts. We constantly monitor  the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, financial data and competitor developments in the global Life Sciences industry.

As COVID-19 surges in the United States and around the world, health officials are responding with stern warnings, more testing and cutbacks on closings. While some nations have virtually stopped the spread within their country, MedTech prepares for a post-COVID world and how the virus and the response to it will reshape the industry.

The following is a small sampling of the COVID-19 updates compiled, reviewed and posted in real-time by our SmartTRAK analysts, who are constantly monitoring the situation and sifting through the noise to present the most relevant news to our subscribers:

As the international response to COVID-19 shifts to preparing for a potential second wave, the Medtech industry pushes forward with the development and approval of new devices. The following is just a small sampling of the past week's international updates that were curated, compiled, reviewed and posted throughout the day by the expert analysts at SmartTRAK. They sift through the noise to discover the latest international news, industry trends, financial data and competitor developments in the global Life Sciences industry.

This week, our expert analysts have sifted through the noise to present some of the latest product developments and clinical trials from the Neuromodulation industry. At SmartTRAK,  our analysts constantly monitor the worldwide MedTech industry to present real-time news, analysis and financial data. All of our analysts are experts in their field, having worked in business development, marketing and competitive intelligence roles at leading medical device companies.

The following is a small sampling of Neuromodulation segment updates from the past week that were compiled, reviewed and posted throughout the day by the industry-experienced analysts at SmartTRAK:

As states begin to loosen restrictions and we try and put COVID-19 in the rear view mirror, in the words of Bill Gates, "it's going to be a while before we can get back to normal" and companies are going to have to find creative ways to stay connected and engaged while moving forward and getting work done.

The following is a small sampling of Regenerative Medicine segment updates from the past week that were compiled, reviewed and posted in real-time by our SmartTRAK analysts, who are constantly monitoring the situation and sifting through the noise to present news, analysis, studies, trial results, patents and financial data that are most relevant to our subscribers.

We are pleased to announce that Joe Mish has joined the team at SmartTRAK as Director of Sales. Joe has 10+ years experience in medical device sales, with concentration on Joint Replacement and Spine & Robotic Technologies. Prior to joining SmartTRAK, Joe sold and implemented analytic software to manage value-based care and bundled payment, working with Stryker, LDR/ZimmerBiomet and Stryker Performance Solutions.

Meet Joe Mish:

What is your role with SmartTRAK? I will be joining the commercial team as Director of Sales.

What do you like about SmartTRAK? I’ll give you two perspectives here. First, with regards to the technology, I love the value proposition to our current and prospective customers. With the world being so volatile and business being severely disrupted (especially for surgery and device companies) being able to offer a solution to reduce risk, improve profitability and productivity makes this a fantastic time to partner with organization’s and build strong, long-lasting relationships. This was truly a deciding factor in making a career/company change. Second, with regards to the company, I love the people. Coming from multiple large Fortune 500 companies with very specific cultures, individuals and team comradery is often and easily overlooked. I have been so impressed with the professionalism, transparency and family vibe from every person I have engaged with and I have only been on board for a week! This feels like a very special group of incredibly talented people and I am honored to be a part of it.